Risk assessment of germline transmission of adeno-associated virul vector of chimeric serotype PHP.eB into mouse oocytes

Aim. To assess the risk of germline transmission of an adeno-associated virul vector of the chimeric serotype PHP. eB into the germ cells of female mice based on the development of an original method for obtaining mouse oocytes devoid of somatic cells and free vector particles.
Materials and methods. The vector under study was administered intravenously to female outbred CD-1 mice at a dose of 5 × 10¹⁰ vector genomes/mouse using an original technique which included hormonal superovulation of exposed animals, oocyte isolation, their purification from contaminating somatic cells, and direct quantitative PCR on lysed oocytes. The vector DNA content in the brain tissue, ovaries, and oocytes was assessed on days 1, 3, 7, 14, 30, and 90 after vector administration.
Results. Using the developed technique, we examined the ability of the adeno-associated virus vector of the chimeric serotype PHP.eB to undergo germline transmission into mouse oocytes. It was established that, despite persistence in brain and ovarian tissue for up to 3 months, vector DNA was not detected in oocytes at any time after vector administration.
Conclusion. The obtained data demonstrate the absence of germline transmission of the studied genetic construct into mouse oocytes. The detection of the adeno-associated vector in the ovaries, despite its absence in oocytes, confirms the effectiveness of the developed technique for obtaining mouse oocytes uncontaminated with somatic cells.

1. Arabi F., Mansouri V., Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomedicine & Pharmacotherapy. 2022;153:113324. DOI: 10.1016/j.biopha.2022.113324.

2. Макаревич П.И. Три десятилетия развития генной терапии: вехи и перспективы. Регенерация органов и тканей. 2023;1(1):16-24. DOI: 10.60043/2949-5938-2023-1-16-24.

3. Bittlinger M., Hoffmann D., Sierawska A.K., Mertz M., Schambach A., Strech D. Risk assessment in gene therapy and somatic genome-editing: An expert interview study. Gene and Genome Editing. 2022;3-4:100011. DOI: 10.1016/j.ggedit.2022.100011.

4. Астапова О.В., Берчатова А.А. Генотерапевтические препараты: аспекты доклинического изучения безопасности. Безопасность и риск фармакотерапии. 2023;11(1):73-96. DOI: 10.30895/2312-7821-2023-11-1-329.

5. Moffit J.S., Blanset D.L., Lynch J.L., MacLachlan T.K., Meyer K.E., Whiteley L.O. et al. Regulatory consideration for the nonclinical safety assessment of gene therapies. Hum. Gene Ther. 2022;33(21-22):1126-1141. DOI: 10.1089/hum.2022.090.

6. ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products (EMA/CHMP/ICH/318372/2021).

7. Quality, preclinical and clinical aspects of gene therapy medicinal products - Scientific guideline. (EMA/CAT/80183/2014.EMA, 2018).

8. ICH Considerations. General principles to address the risk of inadvertent germline integration of gene therapy vectors (CHMP/ICH/469991/2006).

9. Non-clinical testing for inadvertent germline transmission of gene transfer vectors - Scientific guideline. (EMEA/273974/2005. EMA, 2006).

10. Chan K.Y., Jang M.J., Yoo B.B., Ravi N., Wu W.L., Sanchez-Guardado L. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 2017;20(8):1172-1179. DOI: 10.1038/nn.4593.

11. Esmagambetov I.B., Ryabova E.I., Derkaev A.A., Shcheblyakov D.V., Dolzhikova I.V., Favorskaya I.A. et al. rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19. Front. Immunol. 2023;14. DOI: 10.3389/fimmu.2023.1129245.

12. Derkaev A.A., Ryabova E.I., Esmagambetov I.B., Shcheblyakov D.V., Godakova S.A., Vinogradova I.D. et al. rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis. Front. Microbiol. 2022;13:960937. DOI: 10.3389/fmicb.2022.960937.

13. Рябова Е.И., Деркаев А.А., Есмагамбетов И.Б., Щебляков Д.В., Довгий М.А., Бырихина Д.В. и др. Сравнение различных технологий получения рекомбинантного аденоассоциированного вируса в лабораторном масштабе. БИОпрепараты. Профилактика, диагностика, лечение. 2021;21(4):266-278. DOI: 10.30895/2221-996X-2021-21-4-266-278.

14. Плигина К.Л., Жанатаев А.К., Чайка З.В., Дурнев А.Д. Методика цитогенетического анализа ооцитов мышей. Бюллетень экспериментальной биологии и медицины. 2013;156(7):128–132. DOI: 10.1007/s10517-013-2292-0.

15. Tsuchiya S., Sueoka K., Matsuda N., Tanigaki R., Asada H., Hashiba T. et al. The “spanning protocol”: a new DNA extraction method for efficient single-cell genetic diagnosis. J. Assist. Reprod. Genet. 2005;22(11–12):407–414. DOI: 10.1007/s10815-005-7482-x.

16. Ma H., Bell K.N., Loker R.N. qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies. Mol. Ther. Methods Clin. Dev. 2021;20:152–168. DOI: 10.1016/j.omtm.2020.11.007.

17. Martín-Coello J., Gonzalez R., Crespo C., Gomendio M., Roldan E.R.S. Superovulation and in vitro oocyte maturation in three species of mice (Mus musculus, Mus spretus and Mus spicilegus). Theriogenology. 2008;70(6):1004–1013. DOI: 10.1016/j.theriogenology.2008.06.002.

18. Okada H., Hirose Y., Manonmani P., Ito M., Sankai T. Zona-float method for separating mouse eggs from other cells. Exp. Anim. 2004;53(4):355–359. DOI: 10.1538/expanim.53.355.

19. Mahrous E., Yang Q., Clarke H.J. Regulation of mitochondrial DNA accumulation during oocyte growth and meiotic maturation in the mouse. Reproduction. 2012;144(2):177–185. DOI: 10.1530/REP-12-0113.

20. Forootan A., Sjöback R., Björkman J., Sjögreen B., Linz L., Kubista M. Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR). Biomol. Detect. Quantif. 2017;12:1–6. DOI: 10.1016/j.bdq.2017.04.001.

21. Andrade G.M., del Collado M., Meirelles F.V., da Silveira J.C., Perecin F. Intrafollicular barriers and cellular interactions during ovarian follicle development. Anim. Reprod. 16(3):485–496. DOI: 10.21451/1984-3143-AR2019-0051.

22. Zhou H., Ohno N., Terada N., Saitoh S., Fujii Y., Ohno S. Involvement of follicular basement membrane and vascular endothelium in blood follicle barrier formation of mice revealed by “in vivo cryotechnique.” Reproduction. 2007;134(2):307–317. DOI: 10.1530/REP-07-0062.

23. Krivonogova A.S., Bruter A.V., Makutina V.A., Okulova Y.D., Ilchuk L.A., Kubekina M.V. et al. AAV infection of bovine embryos: Novel, simple and effective tool for genome editing. Theriogenology. 2022;193:77–86. DOI: 10.1016/j.theriogenology.2022.09.007.

24. Sato M., Sato-Yamamoto N., Wakita A., Haraguchi M., Shimonishi M., Okuno H. Direct Injection of recombinant AAV-containing solution into the oviductal lumen of pregnant mice caused in situ infection of both preimplantation embryos and oviductal epithelium. Int. J. Mol. Sci. 2022;23(9):4897. DOI: 10.3390/ijms23094897.

25. Kanatsu-Shinohara M., Lee J., Miyazaki T., Morimoto H., Shinohara T. Adeno-associated-virus-mediated gene delivery to ovaries restores fertility in congenital infertile mice. Cell Rep. Med. 2022;3(5):100606. DOI: 10.1016/j.xcrm.2022.100606.

26. Urbanelli L., Buratta S., Tancini B., Sagini K., Delo F., Porcellati S. et al. The role of extracellular vesicles in viral infection and transmission. Vaccines (Basel). 2019;7(3):102. DOI: 10.3390/vaccines7030102.

27. Hu X.L., Zhou X.P., Qian Y.L., Wu G.Y., Ye Y.H., Zhu Y.M. The presence and expression of the hepatitis B virus in human oocytes and embryos. Hum. Reprod. 2011;26(7):1860–1867. DOI: 10.1093/humrep/der103.

28. Ajayi A.F., Akhigbe R.E. Staging of the estrous cycle and induction of estrus in experimental rodents: an update. Fertil. Res. Pract. 2020;6:5. DOI: 10.1186/s40738-020-00074-3.

29. Aizawa R., Ibayashi M., Mitsui J., Tsukamoto S. Lipid droplet formation is spatiotemporally regulated in oocytes during follicular development in mice. J. Reprod. Dev. 2024;70(1):18–24. DOI: 10.1262/jrd.2023-055.

30. Pupo A., Fernández A., Low S.H., François A., Suarez-Amaran L., Samulski R.J. AAV vectors: The Rubik’s cube of human gene therapy. Mol. Ther. 2022;30(12):3515–3541. DOI: 10.1016/j.ymthe.2022.09.015.

31. Batista A.R., King O.D., Reardon C.P., Davis C., Shankaracharya, Philip V. et al. Ly6a differential expression in bloodbrain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B. Hum. Gene Ther. 2020;31(1–2):90–102. DOI: 10.1089/hum.2019.186.

32. Walkey C.J., Snow K.J., Bulcha J., Cox A.R., Martinez A.E., Ljungberg M.C. et al. A comprehensive atlas of AAV tropism in the mouse. Mol. Ther. 2025;33(3):1282–1299. DOI: 10.1016/j.ymthe.2025.01.041.

33. Zhao J., Yue Y., Patel A., Wasala L., Karp J.F., Zhang K. et al. High-resolution histological landscape of AAV DNA distribution in cellular compartments and tissues following local and systemic injection. Mol. Ther. Methods Clin. Dev. 2020;18:856–868. DOI: 10.1016/j.omtm.2020.08.006.

34. Sarkar R., Xiao W., Kazazian H.H. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J. Thromb. Haemost. 2003;1(2):220–226. DOI: 10.1046/j.1538-7836.2003.00096.x.

35. Ferla R., Alliegro M., Marteau J.B., Dell’Anno M., Nusco E., Pouillot S. et al. Non-clinical safety and efficacy of an AAV2/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI. Mol. Ther. Methods Clin. Dev. 2017;6:143–158. DOI: 10.1016/j.omtm.2017.07.004.